HER2

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

HER2
Mar 27, 2025, 13:34 | Blog
Dennis Slamon and Sujuan Ba on HER2 Cancers - NFCR
National Foundation for Cancer Research (NFCR) shared a post on LinkedIn: "In Episode 3 of…
Mar 19, 2025, 15:48 | Science
Oscar Tahuahua: Systematic Review and Meta-analysis in HER2+ Breast Cancer Patients
Oscar Tahuahua, Medical Oncology Fellow at National Cancer Institute(Mexico), shared an article by Shunsuke Nakatani,…
Mar 4, 2025, 11:22 | Science
Heidi Ko: Our latest mini-review on HER2 as a tumor-agnostic biomarker
Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared an article on…
Mar 4, 2025, 11:18 | Blog
Elvina Almuradova: ENHERTU Brings New Hope for Gastric Cancer
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a…
Mar 4, 2025, 05:32 | Science
Erick Saldanha: Proud to wrap up February with 2 publications
Erick Saldanha, Medical Oncologist and Postdoctoral Clinical Fellow at Princess Margaret Cancer Centre, shared a…
Feb 27, 2025, 11:33 | Science
Francisco J. Esteva: The practical implications of HER2-Low and HER2-Ultralow breast cancer
Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill…
Feb 20, 2025, 07:40 | Science
Francisco J. Esteva: What should be the primary endpoint for FDA registration trials in early-stage breast cancer?
Francisco J. Esteva, Professor of Medicine at the Zucker School of Medicine, shared an article…
Feb 11, 2025, 07:57 | Blog
Maria (Masha) Babak: A significant step forward for advanced HR+ HER2-negative breast cancer
Maria (Masha) Babak, Head of The Babak Lab and an Assistant Professor at the City…
Feb 6, 2025, 16:38 | Blog
HER2-positive breast cancer accounts for about 20% of all breast cancer cases - SPCC
SPCC (Sharing Progress in Cancer Care) reshared a post by Definitive Trial on LinkedIn, adding:…
Jan 29, 2025, 18:07 | Blog
The addition of pembrolizumab to neoadjuvant chemotherapy in the phase III KEYNOTE-756 - European Society for Medical Oncology
ESMO - European Society for Medical Oncology shared a post on LinkedIn: "The addition of…
Jan 26, 2025, 14:23 | Blog
Marcia Cruz-Correa: Gastric Cancer 1st line therapy biomarkers at ASCO GI 2025
Marcia Cruz-Correa, Chief Medical Officer at PanOncology Trials, shared a post on X: "Participating in…
Jan 26, 2025, 08:44 | Science
Paolo Cotzia: The safety and effectiveness of combining two intratumoral immunotherapies for treating high-risk DCIS
Paolo Cotzia, Medical Director of Molecular Pathology and Head of Molecular Excellence at Sonic Healthcare…
Jan 25, 2025, 16:19 | Science
Paolo Tarantino: Evolutions in the treatment of HER2+ breast cancer
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared an article by Tess A. O'Meara…
Jan 20, 2025, 13:32 | Science
Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
Kristina Jankovic, Medical Oncology Resident at the University Clinical Center Niš, shared an article by…
Jan 20, 2025, 02:16 | Science
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared an article by Alicia F. C.…
Dec 24, 2024, 13:29 | Science
Francesco Schettini: Which ADC is to prioritise in HR+ and TN BC?
Francesco Schettini, Medical Oncologist at the Breast Unit of the Hospital Clinic of Barcelona and…
Dec 22, 2024, 13:11 | Blog
Akhil Santhosh: Important changes in the latest ESMO BTC guidelines
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre & Research Institute, shared a post…
Dec 14, 2024, 16:05 | Blog
Stephanie Graff: First 3rd-generation HER2-directed ADC in neoadjuvant HER2+ Breast Cancer
Stephanie Graff, Director of Breast Oncology at Brown University Health and an Associate Professor of…
Dec 14, 2024, 15:44 | Blog
Sara Tolaney: First line treatment approaches in HER2+ BC
Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared a…
Dec 14, 2024, 07:35 | Blog
Francisco J. Esteva: Evolving nature of HER2 biomarkers
Francisco J. Esteva, Professor of Medicine at Zucker School of Medicine and Chief of Division…
Dec 11, 2024, 17:44 | Blog
Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC
Mediamedic shared a post on LinkedIn: "Editor’s Note: EGFR mutations are among the most common…
Dec 11, 2024, 17:38 | Blog
SABCS24 Day 1 Highlights by Oncology Brothers
Oncology Brothers shared a post on X: "SABCS24 Day 1 Highlights CommunityOnc: FDA Oncology Reviews recent…
Dec 4, 2024, 10:39 | Insight
Elisa Agostinetto: The Results of the NEOENDO Translational Study by Francesco Schettini, et al.
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared an article by…
Dec 2, 2024, 08:12 | Insight
Mattia Rediti: Our work describing HER2-positive Breast Cancer heterogeneity is out
Mattia Rediti, Medical Oncologist and Bioinformatician and AIRC Postdoctoral researcher at the Metabolic reprogramming in…
Dec 1, 2024, 11:07 | Blog
FDA approved Zanidatamab to treat Advanced Metastatic Biliary Tract Cancers - Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer shared a post on LinkedIn: "The FDA has approved the drug…
Nov 24, 2024, 04:47 | Blog
Zanidatamab is approved by US FDA based off Herizon BTC01
Oncology Brothers shared a post on X: "Zanidatamab (bispecific antibody against Her2) now US FDA…
Nov 21, 2024, 16:37 | Blog
Pashtoon Kasi: New Drug approval for HER2+ Biliary Tract Cancer
Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared a post…
Nov 11, 2024, 03:48 | Insight
Trastuzumab Deruxtecan in Advanced Solid Tumors With HER 2 Amplification Identified
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, shared an…
Nov 8, 2024, 06:58 | Insight
Elisa Agostinetto: Camizestrant vs Fulvestrant for estrogen receptor-positive, HER2-negative breast cancer
Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared an article by…
Nov 2, 2024, 12:01 | Positive
Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024
As Pink October has ended, it's time to reflect on Breast Cancer Awareness Month. OncoDaily…
Nov 2, 2024, 05:07 | Blog
Razelle Kurzrock: Expanding HER2 horizons - Implications for NSCLC and beyond
Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center,…
Oct 29, 2024, 09:31 | Blog
Tumor Board Tuesday on HER2 options for metastatic bladder cancer
Tumor Board Tuesday shared a post on X: "It is amazing how many HER2 options there…
Oct 26, 2024, 18:39 | Insight
EMBER-4 Clinical Trial for Early Breast Cancer
The EMBER-4 clinical trial has been launched to evaluate the effectiveness of imlunestrant compared to…
Oct 9, 2024, 15:40 | Blog
Tanja Obradovic: Orum Therapeutics is focusing its innovation pipeline on degrader-antibody conjugates
Tanja Obradovic shared a post on LinkedIn: "Great news from Orum Therapeutics, a Korea based biotech…
Oct 4, 2024, 17:28 | Blog
Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer
Raffaele Colombo shared a post on X: "sBLA for trastuzumab deruxtecan (T-DXd) has been accepted…
Oct 3, 2024, 07:28 | Blog
Exploring HER2 targeting in Solid Tumours focusing on NSCLC - touch RESPIRATORY
touch RESPIRATORY shared a post on X: "HER2 targeting insights! Join leading experts Dr Razelle…
Oct 2, 2024, 18:59 | Blog
Jin Zhang: Exploring Precision Treatment in Breast Cancer and Advances in Anti-HER2 Therapy - MediaMedic
MediaMedic shared a post on LinkedIn: "2024 COMB丨Dr. Jin Zhang: Exploring Precision Treatment in Breast Cancer…
Oct 2, 2024, 18:56 | Blog
Advancing science for people living with HER2-positive biliary tract cancer - Jazz Pharmaceuticals
Jazz Pharmaceuticals shared a post on LinkedIn: "Biliary tract cancer (BTC) is a relatively rare cancer…
Sep 17, 2024, 16:28 | Blog
Amalya Sargsyan: DestinyGastric03 trial results and HER2+ treatment insights at ESMO24
Amalya Sargsyan posted the following on X: “Great insights from Yelena Janjigian, MD at ESMO24!…
Aug 28, 2024, 17:09 | Blog
Tanja Obradovic: Importance of vigilant toxicity monitoring
Tanja Obradovic shared a post on LinkedIn: "Importance of vigilant toxicity monitoring as well as early…
Aug 28, 2024, 14:41 | Insight
Targeting HER2-low gastric cancer, summary by Erman Akkus
Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, shared a recent article…
Aug 12, 2024, 16:45 | Blog
Chul Kim on the advances in treating lung cancer with exon 20 or mutation at DCLung24
Stephen V Liu shared on X: "Dr. Chul Kim will discuss advances in treating lung…
Aug 9, 2024, 02:14 | Insight
T-DXd in HER2 - Expressing Biliary Tract Cancer
Yakup Ergün, Medical Oncologist at Batman World Hospital, shared on X about a recent paper…
Aug 7, 2024, 17:00 | Insight
Amol Akhade summarising Destiny CRC02
Amol Akhade shared on X: "Destiny CRC02. Trastuzumab deruxtecan in metastatic CRC with 3 to…
Aug 7, 2024, 16:01 | Insight
Piotr Wysocki: Trastuzumab Deruxtecan Shows Promise in Treating HER2-Positive Biliary Tract Cancer
Piotr Wysocki recently shared on LinkedIn: "A recent phase II clinical trial conducted across five…
Jul 25, 2024, 07:47 | Insight
HER2-targeted therapies beyond breast cancer
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a…
Jul 22, 2024, 23:09 | Blog
Aleix Prat: TNBC-DX - new genomic profiling tool for the treatment of early-stage triple-negative breast cancer (TNBC)
Aleix Prat, Director of Cancer Institute and Blood Disorders at Clinical Hospital of Barcelona, shared…
Jul 16, 2024, 13:20 | Blog
Mya Tran: Another year of many developments in precision medicine
Mya Tran, Thoracic Clinical Pharmacist, PharmD, BCOP, at Indiana University Health - Simon Comprehensive Cancer Center,…
Jun 29, 2024, 09:05 | Blog
Erika Hamilton: Always worth major celebration when we see survival improve by 10 months in metastatic cancer
Erika Hamilton shared a post by Healthbook on LinkedIn, adding: "Always worth major celebration when we…
Jun 27, 2024, 12:32 | Insight
Michael Klichinsky: Carisma Therapeutics received FDA Fast Track Designation for CT-0525
Michael Klichinsky, Co-Founder and Chief Scientific Officer at Carisma Therapeutics, shared on LinkedIn: “We are…
Jun 26, 2024, 03:18 | Insight
Paolo Tarantino: The 5 S rules help memorizing a simple framework to manage ILD
Paolo Tarantino shared on LinkedIn: “T-DXd is rapidly expanding in indications, from HER2+, to HER2-low, and…
Jun 25, 2024, 16:01 | Insight
Paolo Tarantino: Phase 1 trial of the HER2 topo1 ADC SHR-A1811 out in Journal of Clinical Oncology
Paolo Tarantino shared on X:  . "Phase 1 trial of the HER2 topo1 ADC SHR-A1811…
Jun 25, 2024, 07:47 | Blog
Mark Lewis: It is UNACCEPTABLE to treat mCRC without knowing these biomarker
Mark Lewis shared a post by FDA Oncology on X, adding the following:   . “We…
Jun 23, 2024, 10:53 | Blog
Breaking Science in Breast Cancer with Hope Rugo - ESMO
ESMO shared a post on LinkedIn: "For ESMO members: Breaking Science in Breast Cancer. Hope Rugo…
Jun 20, 2024, 16:00 | Insight
Andrew Parsonson: Median pooled OS over 5 years for MBC on first line ET and CDK4/6
Andrew Parsonson, Medical Oncologist at Nepean Blue Mountains Local Health District (NBMLHD), shared a post…
May 29, 2024, 08:20 | Blog
Paolo Tarantino: In this work by the AZ translational team, QCS proved superior to manual IHC in predicting the activity of T-DXd
Paolo Tarantino shared a post on X: "In the ph1 trial of T-DXd in HER2-low MBC,…
May 29, 2024, 03:24 | Insight
Ibrahim Sahin: Just had chance to read the full article on ‘HER2 amplified’ CRC
Ibrahim Sahin, Assistant Professor at UPMC Hillman Cancer Center, shared a post on X: “Just…
May 26, 2024, 06:49 | Societies
Paolo Tarantino: Less than a week to what promises to be a terrific ASCO24
Paolo Tarantino recently shared a post on X: "Less than a week to what promises…
May 25, 2024, 11:59 | Blog
Vivek Subbiah: ASCO 24 time to learn the latest and greatest in Tissue Agnostic Precision Medicine
Vivek Subbiah shared on X: “It's ASCO 24 time Mark your calendars to learn the latest…
May 24, 2024, 00:58 | Blog
Francisco J. Esteva on the DESTINY-Breast06 trial
Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared…
May 21, 2024, 07:42 | Blog
Chiara Molinelli: Check out our poster at ESMOBreast24
Chiara Molinelli, Oncologist and Medical Research Fellow at Ospedale San Martino Genova, shared a post…
May 19, 2024, 10:55 | Insight
Dhruba Deb: The 8 SCLC projects Lung Cancer Research Foundation recently funded
Dhruba Deb, Senior Director of Research and Administration at Lung Cancer Research Foundation, shared on…
May 17, 2024, 12:54 | Insight
Piotr Wysocki: Anti-HER2 treatment in patients with advanced biliary cancer
Piotr Wysocki recently posted on LinkedIn: "The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is…
May 16, 2024, 09:09 | Blog
Kohei Shitara: Happy to report biomarkers in DESTINIY GC01 at Nature Medicine
Kohei Shitara, Medical oncologist at National Cancer Center Hospital East, Japan shared a post on X:…
May 11, 2024, 11:23 | Insight
Matt Sagan: Moving from HER2+ to HER2-low to HER2- ultralow
Matt Sagan, Co-Founder and CEO of FiBioMed, shared a post by Paolo Tarantino on X,…
May 2, 2024, 15:20 | Blog
Paolo Tarantino: Impressive to think at the journey of ADCs over the last five years
Paolo Tarantino shared on LinkedIn: "Impressive to think at the journey of ADCs over the last…
May 1, 2024, 12:05 | Blog
Paolo Tarantino: Refresher for the current and upcoming definitions of HER2 in breast oncology
Paolo Tarantino shared on X/Twitter: "Refresher for the current and upcoming definitions of HER2 in breast…
Apr 28, 2024, 05:14 | Insight
Aleix Prat: Our new article about attitudes towards HER2DX in Spain
Aleix Prat, Director of the Cancer Institute at Hospital Clinic of Barcelona, shared on X/Twitter:…
Apr 26, 2024, 17:44 | Drugs
Paolo Tarantino: The agnostic potential of Antibody Drug Conjugates with Roberto Carmagnani Pestana, MD is among the most cited of 2022-2023 on CA - A Cancer Journal for Clinicians
Apr 21, 2024, 11:35 | Insight
Samuel Kareff: Our pan-tumor analysis on the not-so-elusive HRAS mutation in solid tumors
Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, shared…
Apr 20, 2024, 20:17 | Insight
Paolo Tarantino: Tumor-infiltrating lymphocytes (TILs): not only prognostic in Triple-Negative Breast Cancer
Paolo Tarantino, Research fellow at Dana Farber Cancer Institute, shared on X: "Tumor-infiltrating lymphocytes (TILs): not…
Apr 12, 2024, 05:16 | Drugs
Tanja Obradovic: Era of antibody drug conjugates just got even more exciting with the first tumor-agnostic approval for ADC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: "Era…
Apr 11, 2024, 08:13 | Drugs
Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma
Tom Powles, Director of Barts Cancer Center, recently shared on X: “Trial in progress: The…
Apr 8, 2024, 15:41 | Drugs
Tom Powles: This seems an ambitious accelerated approval in UC
Tom Powles, Director of Barts Cancer Center, recently shared on X: "TDXD received FDA accelerated…
Apr 8, 2024, 03:54 | Drugs
Paolo Tarantino: Trastuzumab deruxtecan is now FDA approved for ANY treatment-refractory HER2+ solid tumor
Paolo Tarantino, Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute, shared…
Mar 22, 2024, 06:12 | Drugs
Paolo Tarantino: We’re running SATEEN, the first trial of sacituzumab govitecan + trastuzumab in patients with HER2 + MBC
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post by Marta…
Mar 21, 2024, 10:54 | Insight
The Swedish SCAN-B cohort, the HER2DX risk-score was found significantly associated with OS after adjustment for clinical variables and treatment regimen - ESMO Open
ESMO Open posted on X: "Hot off the press: among 757 patients with early HER2+ breast…
Mar 18, 2024, 19:11 | Blog
Fredrick Chite Asirwa: International Cancer Institute clinic is recruiting breast cancer patients for clinical trials currently
Fredrick Chite Asirwa, CEO/Executive Director of International Cancer Institute, posted on LinkedIn: "To contribute to…
Mar 16, 2024, 20:07 | Insight
Erman Akkus: HER2 and mCRC on Journal of Clinical Oncology
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "HER2 and mCRC on…
Mar 12, 2024, 21:01 | Blog
Rebecca Shatsky: Got to meet the fantastic Sumanta Pal in person finally, as well as his incredible fellow
Rebecca Shatsky and Sumanta Pal, Professor and Vice Chair of Academic Affairs, City of Hope…
Feb 18, 2024, 13:29 | Blog
Aydah AlAwadhi: Delighted to have been part of the 12th Annual Beirut Breast Cancer Conference
Aydah AlAwadhi, Consultant Medical Oncologist at Abu Dhabi Health Services Company, recently posted on LinkedIn:…
Feb 11, 2024, 15:45 | Blog
Paolo Tarantino: In a large RW cohort we found that nearly 30% of breast tumors changed HER2 status after neoadjuvant treatment
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter: “In…
Feb 8, 2024, 17:54 | Insight
Paolo Tarantino: Few treatments in oncology allow to achieve more than 50% intracranial response rates, with durable efficacy
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared ESMO Open's post on X/Twitter, adding: "One…
Feb 1, 2024, 15:19 | Opinion
Paolo Tarantino: Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared by Niklas…
Jan 14, 2024, 15:07 | Insight
Francisco J. Esteva: The evolution of HER2 as a pivotal biomarker in breast cancer diagnosis and treatment is a fascinating story
Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital,…
Jan 10, 2024, 18:21 | Blog
Top Precision Oncology articles of 2023 by Vivek Subbiah
Vivek Subbiah shared on X/Twitter: "By popular demand delighted to share the 'Top Precision Oncology…
Dec 14, 2023, 16:23 | Insight
SABCS23 Day 1 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the first day's…
Jul 27, 2023, 07:14 | Blog
DAISY Such a key publication in our growing understanding of T-DXd - Stephanie Graff
DAISY Such a key publication in our growing understanding of T-DXd, particularly across the spectrum…
Jul 14, 2023, 02:41 | Insight
HER2 protein and mRNA expression and amplifications among 5,305 diverse cancers is HIGHLY VARIABLE - Jacob J. Adashek, DO
OUT TODAY in JCO Precision Oncology with Medical College, Dr. Razelle Kurzrock! HER2 protein and…
Jul 10, 2023, 04:23 | Insight
Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer - Stephanie Graff, MD, FACP
Now in ⁦ CBC journal ⁩: Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast…
Jun 14, 2023, 18:35 | Drugs
Can we improve the delivery of eribulin by linking it to a HER2 mAb?
In a post by Paolo Tarantino on Twitter, it says, "Can we improve the delivery…
Jun 6, 2023, 19:11 | Opinion
HER2-low is a dynamic, rather than static definition! - Paolo Tarantino
Retrospective HER2-low analysis of 512 patients with TNBC presented by Yale Bar. confirms high discordance…
All: 92 Posts: 1 - 100
Special Coverage